![Munich, Germany-based SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2 antibodies, announced the closing of a EUR 63 million (USD 70 million) Series A financing round.](https://startuprise.co.uk/wp-content/uploads/2024/07/SciRhom.webp)
Munich, Germany-based SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2 antibodies, announced the closing of a EUR 63 million (USD 70 million) Series A financing round.
SUMMARY
- Munich, Germany-based SciRhom GmbH, a biopharmaceutical company announced the closing of a EUR 63 million (USD 70 million) Series A financing round.
- SciRhom translating world-leading expertise in the TACE/ADAM17 pathway and its central role in autoimmunity and other indications into breakthrough biopharmaceuticals.
The round was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners, with participation from new investor Bayern Kapital and existing investors including High-Tech Gründerfonds (HTGF) and PhiFund Ventures from New York, USA. The new funds will be used to accelerate and broaden the impact of the company’s innovative therapeutic strategy in autoimmune disorders. The first clinical study evaluating SR-878, a highly specific monoclonal antibody for iRhom2, is expected to start dosing in the second half of 2024.
Read also - Trustap funding news- Marketplace Transaction Platform Trustap Secures €5.08 Million in Funding
RECOMMENDED FOR YOU
![recomd](https://startuprise.co.uk/wp-content/uploads/2024/06/Hamburg-based-DealCircle-Raises-7-figure-funding-.webp)
DealCircle funding news – Hamburg-based DealCircle Raises 7-figure funding
Startup Rise EU
Jun 20, 2024
![recomd](https://startuprise.co.uk/wp-content/uploads/2024/01/Paris-based-foodtech-Standing-Ovation-Secures-E3-Million-in-Funding.webp)
[Funding alert] Paris-based foodtech Standing Ovation Secures €3 Million in Funding
Startup Rise EU
Jan 10, 2024
![recomd](https://startuprise.co.uk/wp-content/uploads/2024/05/Security-Platform-Aikido-Secures-over-E15.8-Million-in-Fresh-Series-A-Round-Funding.webp)
Aikido funding news – Security Platform Aikido Secures over €15.8 Million in Fresh Series A Round Funding
Startup Rise EU
May 2, 2024
SciRhom was founded with the mission to provide a new treatment paradigm for autoimmune diseases and potentially other indications by selectively addressing TACE/ADAM17, a master switch for various autoimmune disease-relevant signaling pathways, via iRhom2. The SciRhom team collaborated closely with co-founders Prof. Carl Blobel and Hospital for Special Surgery (HSS), the world’s leading academic medical center specialized in Rheumatology and musculoskeletal health, where Prof. Blobel serves as Director of the Arthritis and Tissue Degeneration Program. He has made seminal contributions to the understanding of how iRhom2 controls the activity of TACE/ADAM17 in inflammation and autoimmune diseases. SciRhom designed its most advanced development candidate SR-878 to simultaneously block several pro-inflammatory and disease-driving pathways, including TNF-alpha, IL-6R, and EGFR signaling, while preserving other vital functions dependent on TACE/ADAM17.
This unique ability to attack multiple cytokines and to potentially promote immune tolerance through restoring beneficial TNFR2 signaling, and regulatory T-cell expansion promises to have a transformative effect in patients across a wide range of autoimmune diseases. Moreover, the selective targeting of iRhom2 is expected to have a favorable safety profile.
"Since its foundation, SciRhom has applied rigorous science to establish a leading position in iRhom2-targeting biopharmaceuticals including a comprehensive IND/CTA-enabling data and CMC package and strong patent protection. Now is the time to shift gears and accelerate our novel and potentially groundbreaking therapeutic strategy toward clinical proof-of-concept and beyond to reach patients in need of better autoimmune treatments,” commented co-founder Dr. Jens Ruhe, Managing Director & COO of SciRhom.
Based on positive preclinical data sets generated in vitro and in established animal models of rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), SciRhom has advanced its first program to a Phase 1-ready stage. As announced on June 12th, 2024, the first CTA approval was achieved paving the way for initiating a first clinical study in Austria in the second half of 2024. The study aims to evaluate safety in healthy volunteers and provide initial evidence of clinical activity in the second part of the study.
Dr. Jan Poth, Managing Director & CEO of SciRhom added: “We are excited to haveattracted such a high-caliber international consortium of investors and appreciate ourexisting shareholders backing SciRhom in this crucial period of its development. We lookforward to collaborating with our new as well as existing partners and board members tobring a differentiated therapeutic option to patients and address the unmet medical needfor much more effective and safe treatments for autoimmune disorders.”
In conjunction with this investment, Dr. Olivier Litzka from Andera Partners, Dr. Peter Neubeck from Kurma Partners, Dr. Georgina Askeland from Hadean Ventures, Dr. Fei Tian from MIG Capital and Dr. Varun Gupta from Wellington Partners will join SciRhom’s Board of Directors.
About SciRhom GmbH
SciRhom translating world-leading expertise in the TACE/ADAM17 pathway and its central role in autoimmunity and other indications into breakthrough biopharmaceuticals. SciRhom developing proprietary and first-in-class iRhom2-targeting therapies and are accelerating our lead antibody program SR-878 into and through clinical development.
With strong support from international lead investors Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, Wellington Partners, as well as Bayern Kapital and current shareholders, SciRhom aims to push the boundaries in autoimmune medicine.
Recommended Stories for You
![story](https://startuprise.co.uk/wp-content/uploads/2024/06/Pharmatech-Company-SkyCell-Secures-116Million-in-Series-D-Round-Funding.webp)
SkyCell funding news – Pharmatech Company SkyCell Secures $116Million in Series D Round Funding
Startup Rise EU Jun 25, 2024